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Discussion
• Compared trials to assess approaches to each factor
• MR CLEAN’s publication interrupted many of the trials, some were unable to 
reach targeted sample size, thus two of the seven had inconclusive results 
(THERAPY, EASI)
• However, most of the trials still had significant results 
• Those that were inconclusive still trended in support of the hypothesis
Conclusion
• Significant increase in 90-day functional independence rate in IVT + MT 
groups vs IVT groups
• No significant difference in 90-day mortality rate between the two groups
• Combinative therapy does have a place in treatment of acute large vessel 
occlusion 
• Areas of further research: 
• how health and economic inequities may hinder implication of MT
• Efficacy in posterior circulation strokes
• Role of MT in later presenting strokes (>6 hours)
• MT stent-retrievers vs MT aspiration
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Introduction
• Strokes affect more than 17 million people annually
• 2nd most common cause of death globally
• Thrombotic and embolic ischemia account for 85% of all strokes
• Standard of treatment for ischemic strokes was IV thrombolysis (IVT), tissue
plasminogen activators (tPA) (ie. alteplase)
• tPA has many exclusionary criteria and was still only moderately
efficacious for small portion of patients
• Less effective for larger clot burdens
Methods
• PubMed, EBISCO, Google Scholar were used for a literature search
• Randomize control trial > Retrospective Cohort Study > Case-control
Studies > Cross-sectional > case reports
• Inclusion Criteria:
• Compared IVT vs IVT + MT (Stent-retriever, Aspiration)
• Treatment time <6 hours of onset of symptoms
• Outcome Measure of 90-day functional independence rate
• Exclusion Criteria:
• systematic reviews or meta-analysis
• did not compare dual therapy with individual therapy
• Studies that observed the effects of one therapy (IV or MT)
• Treatment time >6 hours of symptom onset
• MR CLEAN was not used as its treatments were too varied (used IA tPA, IV
tPA, and/or both IVT/IAT + MT vs supportive treatment)
• This review compared seven trials that fit criteria.
Results
• Analyzed to critique common factors of each articles:
• Control for bias
• Blinding of researchers
• Inclusion and exclusion criteria
• Adherence to treatment time window
• Primary Outcome: 90-day functional independence rate
• Primary Safety Outcome: 90-day mortality rate
• Shortcomings and advantages
Table 2: Validity Assessment. Combination treatment vs. IV thrombolytic
Study Selection Bias Performance Bias Blinding
Time window for 
intervention (<6 hrs)




A A I A A
Saver
(SWIFT PRIME)
A A A A I
Mocco
(THERAPY)
A A A A A
Khoury
(EASI)
A A A A A
Campbell 
(EXTEND-IA)
A A A A A
Muir
(PISTE)
A A A A A
Cabral et al I A A A I
Table 3: Comparison of Results. Combination treatment vs. IV thrombolytic
Study
IVT
mRS = 0-2 at 90 days
Combination Treatment
mRS = 0-2 at 90 days
IVT Mortality at 90 
days (%)




S S NS NS
Saver
(SWIFT PRIME)
S S NS NS
Mocco
(THERAPY)
I I I I
Khoury
(EASI)
I I I I
Campbell 
(EXTEND-IA)
S S NS NS
Muir
(PISTE)
S S NS NS
Cabral et al S S NS NS
Key: A: Adequate, assessment/measure (ie. blinding, intention to treat analysis) was completed and used appropriately through the
study, I: Inadequate evidence, assessment/measure was not completed or discussed in the study. Selection Bias is considered adequate
if the study randomized patients as they were placed into their treatment groups. Performance Bias is adequate if patient factors (ie.
comorbidities, age, sex) were adjusted for in the study’s statistical analysis. Blinding is considered adequate if the study blinded the
analysis process and/or data collection after treatment (ie. staff member was blinded to the treatment group when collecting the mRS
score of the patients at 90 days). Time window for intervention is adequate it patients began treatment within 6 hours of symptoms
onset. Intention-to-treat analysis is adequate if it was performed in each respective study.
Key: IVT: Intravenous therapy, S: Significant (p<0.05), NS: Not Significant (p>0.05), I: inconclusive due to 
interruption of trial
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Key: THRACE: THRombectomie des Artères CErebrales, SWIFT PRIME: Solitaire with the Intention for Thrombectomy as Primary
Endovascular Treatment, THERAPY: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System’s Safety and
Effectiveness in the Treatment of Acute Stroke, EASI: Endovascular acute stroke intervention, EXTEND-IA: Extending the Time for
Thrombolysis in Emergency Neurological Deficits - Intra-Arterial, PISTE: Pragmatic Ischaemic Thrombectomy Evaluation, RCT: Randomized
Control Trial, RCS: Retrospective Cohort Study, CT: Combination treatment) IVT: Intravenous therapy, ICA: Internal Carotid Artery, MCA:
Middle Cerebral Artery, rtPA: recombinant tissue plasminogen activator, NIHSS: National Institutes of Health Stroke Scale, mRS = 0-2 at
90 days: modified Rankin Scale score of 0-2 at 90 days
• MR CLEAN studied use of tPA with other
adjuncts, ie. mechanical thrombectomy (MT)
• Hypothesis: IVT + MT would lead to increased
rate of 90-day functional independence vs.
just IVT alone.
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